Clinical trial · Interventional
An Exercise Trial for Acute Myeloid Leukaemia (AML) Patients Undergoing Induction Chemotherapy
A Phase II Exercise RCT for AML Patients Undergoing Induction Chemotherapy
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Reduced quality of life, fatigue, and loss of physical function are common in patients getting chemotherapy for acute myeloid leukaemia (AML). The investigators completed a pilot study showing that exercise during active chemotherapy for AML is feasible, safe, and may improve symptoms and physical function. The investigators now propose to compare our hospital-based supervised exercise program to usual care to see if exercise can improve symptoms, physical function, and improve treatment tolerability.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Acute Myeloid Leukemia | Acute Myeloid Leukemia | CURATED_BROADER | 0.80 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Exercise | Behavioral | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- type
- EXPERIMENTAL
- label
- Exercise
- description
- Patients will receive an individualized, supervised mixed-modality exercise program created by a CSEP-Certified Exercise Physiologist (CEP).
- interventionNames
- Behavioral: Exercise
- type
- NO_INTERVENTION
- label
- Control
- description
- Participants assigned to this arm will receive usual care.
Primary outcomes (3)
- measure
- Change from baseline in quality of life at weeks 4-6 (post-induction) and weeks 10-12 (post-consolidation 1) (QOL)
- timeFrame
- Baseline (within 5 days of starting chemo), Post-induction (weeks 4-6), Post-consolidation (weeks 10-12)
- description
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Is ≥ 18 years old * Has newly diagnosed AML, or relapsed AML after having been in CR for at least 6 months * Is initiating induction chemotherapy * Is ambulatory without need for human assistance * Has consented to study * Is medically cleared for participation by the attending physician Exclusion Criteria: * Has another active malignancy * Has life expectancy \< 1 month, physician determined * Has significant comorbidity * Has uncontrolled pain * Has haemodynamic instability * Lacks fluency in reading and writing English, and there is no translator available for each visit
References
Publications (0)
Data not yet available